What question did this study set out to answer?

The central aim is to develop and assess an integrated genetic risk model for inherited prostate cancer risk.

Unified genetic risk score for prostate cancer enables improved risk stratification for clinical decision-making

View Full Paper

Ask AI

Bookmark

Authors

Randomized trial evaluates a continuum genetic risk model for improved prostate cancer risk assessment, suggesting better clinical decision-making.

The central aim is to develop and assess an integrated genetic risk model for inherited prostate cancer risk.
Evaluated pathogenic variants and polygenic risk scores in the UK Biobank (n=218484) using Cox models.
Developed the GenProb-PCa model incorporating gene-specific variants and polygenic risk.
Performed external validation in the Genomic Health Initiative cohort (n=6590).
Five genes and the polygenic risk score were independently associated with prostate cancer (p<0.001).
GenProb-PCa demonstrated superior discrimination compared to binary models (C-index 0.69 vs 0.52; p<0.001).
20% of non-pathogenic variant carriers were reclassified to higher risk groups, and 60% of carriers to lower risk groups.

Shi et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark

Randomized trial evaluates a continuum genetic risk model for improved prostate cancer risk assessment, suggesting better clinical decision-making.